Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amenamevir and Ciclosporin DDI Study
NCT02280421Phase 1Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Oct 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Amenamevir in herpes zoster (HZ) and herpes simplex virus infection (2 arms), sponsored by Maruho Co., Ltd. Primary endpoints: Peak Plasma Concentration of ASP2151 at Day 7, Time of Peak Concentration of ASP2151 at Day 7 and 4 more. Started Oct 2014; status: completed.
02
Drugs
Amenamevir
03
Conditions
herpes zoster (HZ)herpes simplex virus infection
Beyond the preview
Go deeper on NCT02280421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02280421.